Uso terapêutico da Cannabis sativa no tratamento da doença de Alzheimer: revisão integrativa
DOI:
https://doi.org/10.11606/issn.1806-6976.smad.2025.227069Palavras-chave:
Doença de Alzheimer, Cannabis, Maconha medicinal, Manifestações neurocomportamentaisResumo
Objetivo: investigar à luz da literatura científica a eficácia do uso terapêutico da Cannabis sativa no tratamento da Doença de Alzheimer. Metodologia: trata-se de uma revisão integrativa da literatura que reuniu artigos a partir de uma metodologia sistematizada. A busca dos estudos se deu através das bases de dados Literatura Latino Americana e do Caribe em Ciências da Saúde, SciVerse Scopus e Web of Science, utilizando Descritores em Ciências da Saúde. Resultados: a amostra incluiu 16 artigos científicos, todos indicando uma crescente tendência na exploração dos compostos da Cannabis sativa para o tratamento sintomático da doença. Estudos experimentais em laboratório são destaques nos achados, bem como a análise da dose ideal não tóxica para eficácia no tratamento. A eficácia no tratamento mostra-se no retardo e/ou diminuição de sintomas comportamentais da doença com consequente melhora da qualidade do contexto familiar envolvido. Conclusão: o uso dos compostos da Cannabis sativa demonstrou eficácia para o tratamento sintomático da pessoa com Alzheimer, o que revela um avanço da medicina e a quebra de paradigmas sobre a planta. As evidências apresentadas lançam luz sobre nuances específicas que podem repercutir não apenas na vida da pessoa com a doença, mas em toda dinâmica familiar.
Downloads
Referências
Araújo SEM, Cunha ER. Marques IL. Paixão AS, Dias AFG. Sousa PM, et al. Alzheimer's disease in Brazil: an epidemiological analysis between 2013 and 2022. Res Soc Dev. 2023;12(2):1-6. https://doi.org/10.33448/rsd-v12i2.40345
Watt G, Karl T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Front Pharmacol. 2017;8:20. https://doi.org/10.3389/fphar.2017.00020
Santos VRT, Santos RA, Guedes JPM, Andrade MC. The use of cannabis in the treatment of Alzheimer. Res Soc Dev. 2022;11(7):e28711729889. https://doi.org/10.33448/rsd-v11i7.29889
Remor KVT, Fraga AC, Mazzucchetti L, Blatt CR, Sakae TM. Alzheimer disease: pharmacological treatment and cognitive performance. Rev AMRIGS [Internet]. 2020 [cited 2024 Jun 11];64(2):207-12. Available from: https://oldsite.amrigs.org.br/assets/images/upload/pdf/jornal/1610631629.pdf#page=41
Costa BGL, Lima LR, Funghetto SS, Volpe CRG, Santos WS, Stival MM. Non-pharmacological methods for Alzheimer’s treatment: na integrative review. Rev Enferm Cent-Oeste Min. 2019;9. https://doi.org/10.19175/recom.v9i0.2786
Pessoa DOC, Lira IV, Siqueira LDP. Cannabis Sativa: an integrative review of legal, toxicological and pharmacotherapeutic aspects. Res Soc Dev. 2021;10(15):e18101522408. https://doi.org/10.33448/rsd-v10i15.22408
Sousa IGD, Marques NM. Descobertas sobre o uso de cannabis na doença de Alzheimer: uma revisão da literatura. In: Anais do VI Congresso Internacional de Envelhecimento Humano. [Internet]; 2019 Jun 26-28; Campina Grande, PB. Campina Grande: Realize Eventos; 2019 [cited 2023 Nov 16]. Available from: https://www.editorarealize.com.br/editora/anais/cieh/2019/TRABALHO_EV125_MD4_SA2_ID2756_27052019222514.pdf
Casarin ST, Porto AR, Gabatz RIB, Bonow CA, Ribeiro JP, Mota MS. Types of literature review: considerations of the editors of the Journal of Nursing and Health. J Nurs Health [Internet]. 2020 [cited 2023 Nov 27];10(5). https://doi.org/10.15210/jonah.v10i5.19924
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4
Agency for Healthcare Research and Quality. Introduction to the Toolkit for using the AHRQ Quality Indicators: how to improve hospital quality and safety [Internet]. Rockville, MD: AHRQ; 2016 [cited 2023 Sept 23]. Available from: https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/hospital/qitoolkit/combined/combined_toolkit.pdf
Bardin L. Análise de Conteúdo. São Paulo: Edições 70; 2016. 288 p.
Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β- amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012;9:8. https://doi.org/10.1186/1742-2094-9-8
Coles M, Watt G, Kreilaus F, Karl T. Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APPSwe/PS1ΔE9 Transgenic Female Mice. Front Pharmacol. 2020;11. https://doi.org/10.3389/fphar.2020.587604
Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease. Mol Neurobiol. 2019;56(11):7719-30. https://doi.org/10.1007/s12035-019-1637-8
Libro R, Diomede F, Scionti D, Piattelli A, Grassi G, Pollastro F, et al. Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016;18(1):26. https://doi.org/10.3390/ijms18010026
Hermush V, Ore L, Stern N, Mizrahi N, Fried M, Krivoshey M, et al. Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Front Med. 2022;9. https://doi.org/10.3389/fmed.2022.951889
Leszko M, Meenrajan S. Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer’s disease. Complement Ther Med. 2021;57:102660. https://doi.org/10.1016/j.ctim.2021.102660
Broers B, Patà Z, Mina A, Wampfler J, de Saussure C, Pautex S. Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva. Med Cannabis Cannabinoids. 2019;2(1):56-9. https://doi.org/10.1159/000498924
Fihurka O, Wang Y, Hong Y, Lin X, Shen N, Yang H, et al. Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer’s Disease. Biomolecules. 2023;13(2):232. https://doi.org/10.3390/biom13020232
Chesworth R, Cheng D, Staub C, Karl T. Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model. Front Pharmacol. 2022;13. https://doi.org/10.3389/fphar.2022.931384
Nitzan K, Ellenbogen L, Bentulila Z, David D, Franko M, Break EP, et al. An Ultra- Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model. Int J Mol Sci. 2022;23(16):9449. https://doi.org/10.3390/ijms23169449
Bittes YP, Ribeiro LB, Anselmo GS, Dantas TCL, Ferreira MVR, Neves WC, et al. Uso dos canabinoides no tratamento de pessoas portadoras de Alzheimer. REVISA [Internet]. 2021 [cited 2023 Oct 13];10(2):887-99. Available from: https://rdcsa.emnuvens.com.br/revista/article/view/467
Timler A, Bulsara C, Bulsara M, Vickery A, Jacques A, Codde J. Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial. Australas J Ageing. 2023;42(4):698-709. https://doi.org/10.1111/ajag.13224
Ruver-Martins AC, Bicca MA, Araujo FS, Maia BHLNS, Pamplona FA, Silva EG, et al. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report. J Med Case Reports. 2022;16(1):277. https://doi.org/10.1186/s13256-022-03457-w
Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and Practices of Cannabis Dispensary Staff. Cannabis Cannabinoid Res. 2016;1(1):244-51. https://doi.org/10.1089/can.2016.0024
Ahmed AIA, van den Elsen GAH, Colbers A, Kramers C, Burger DM, van der Marck MA, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology (Berl). 2015;232(14):2587-95. https://doi.org/10.1007/s00213-015-3889-y
Seniya C, Khan GJ, Uchadia K. Identification of Potential Herbal Inhibitor of Acetylcholinesterase Associated Alzheimer’s Disorders Using Molecular Docking and Molecular Dynamics Simulation. Biochem Res Int. 2014;2014:e705451. https://doi.org/10.1155/2014/705451
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 SMAD, Revista Eletrônica Saúde Mental Álcool e Drogas (Edição em Português)
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
